(Image source from: Canva.com)

Researchers from Stanford University created a new vaccine that protects against various respiratory illnesses, bacteria, and allergens. The research, featured in the journal Science, indicates that one nasal spray vaccine can defend against colds, flu, coughs, and lung infections caused by bacteria. The scientists found that mice were shielded from SARS-CoV-2, other coronaviruses, Staphylococcus aureus, Acinetobacter baumannii, and dust mites. Bali Pulendran, PhD, the Violetta L. Horton Professor II and a microbiology and immunology professor who led the study, mentioned that this new vaccine works against a significantly broad range of respiratory dangers tested. It has been examined in animals and is now awaiting trials in humans. In an interview with BBC, Prof. Pulendran stated, "This vaccine, which we call a universal vaccine, produces a much wider response that helps protect against not only the flu virus or the Covid virus or the common cold virus but nearly all viruses and as many types of bacteria as we have tested, along with allergens too. The way this vaccine operates is completely different from how all previous vaccines have functioned. "

Conventional vaccines teach the body to combat one specific illness, like measles or chickenpox, providing focused protection only for those diseases. In contrast, the new method does not train the immune system; instead, it simulates the way immune cells interact with each other. Administered as a nasal spray, it energizes white blood cells in the lungs. The vaccine puts these cells on "alert" mode, preparing them to fight off any incoming infection. In tests on animals, this increased readiness lasted for around three months, stopping viruses from entering the body through the lungs. For those that did manage to get in, the rest of the immune system was ready to respond quickly, according to Prof. Pulendran. The vaccine also provided protection against two types of bacteria, Staphylococcus aureus and Acinetobacter baumannii. It directed the immune response in a way that lessened reactions to dust mite allergens, a frequent cause of asthma. However, there are numerous hurdles remaining. Though it has been tested as a nasal spray, it may need a nebulizer for deeper penetration into human lungs. It is uncertain if the effects last in humans, how long the "alert" state would endure, or how human immune systems compare to those of mice.

Researchers are preparing to conduct trials on humans by intentionally infecting vaccinated individuals to evaluate how effective the vaccine is. Enhancing immunity beyond normal levels may lead to health issues, so the group plans to do this as an addition to current vaccines, rather than replacing them. In the early days of the pandemic, such as during the COVID outbreak in 2020, a universal vaccine could provide essential support and save lives while waiting for more specific vaccines. Pulendran mentioned, "This would lower death rates, reduce the seriousness of illnesses, and possibly foster a level of immune strength that would have a significant effect. " Alternatively, at the beginning of winter when viruses start circulating, "one could envision a seasonal spray that could provide broad immunity against all of them. " A large number of people in India suffer from lung ailments. Air pollution worsens symptoms of colds, flu, bacterial pneumonia, and allergies. Additionally, household dust mites also trigger asthma, particularly during the humid rainy season and polluted winter months. The new vaccine has the potential to change this situation and offer comprehensive protection against viruses such as SARS-CoV-2, various coronaviruses, bacteria, and allergens.

For individuals in India, this could result in fewer trips to healthcare providers for seasonal coughs and colds. During outbreaks, this vaccine could be crucial in providing extra time, lowering death rates, and increasing resilience among at-risk populations like older adults and children. Furthermore, a seasonal spray before the smog of Diwali or the flu season may assist in preventing asthma episodes. While human testing is necessary to grasp long-term risks like immune system overactivity, the new vaccine could serve as a proactive measure.